PATENT CLAIM ANALYSIS

Application Number: 16158738
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-06
Patent Classification: ["514", "546000"]

Abstract:
Pharmaceutical formulations comprising 9-cis-retinyl esters in a lipid vehicle are described as retinoid replacement therapies for treating retinal degenerations in humans.

Claim (Index 33):
The formulation of  claim 21 , wherein the 11-cis-retinal deficiency is due to an RPE65 mutation.

Metadata:
- Claim Count in Document: 62.0
- Percentile: 97.0
- Lexical Diversity: 1.04762
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15274257', '13090215', '14875342', '13619731', '13619631']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7684338297159247
- 35 USC 102 Novelty (BERT): 0.6547109204304402
- Combined Prediction Score: 0.7570615387873763
- Mean Citation Score: 426.782604
- Max Citation Score: 639.7981
- Similarity Product: 604.5881494377672

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test